Inflammatory Bowel Diseases Clinical Trial
Official title:
Low Residue Diet 3 Days Versus 1 Day as Preparation for Colonoscopy: a Randomized Controlled Trial
Verified date | February 2020 |
Source | Hospital Parc Taulí, Sabadell |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Colonoscopy is the gold-standard for the evaluation of the colorectal mucosa. Colonoscopy
quality indicators are the adenoma detection rate, the rate of cecal intubation and the bowel
preparation.
The role of diet in preparing for colonoscopy is not fully established. Currently there is
not enough evidence available to choice between 3 days of low residue diet versus 1 day.
The research hypothesis is that the low residue diet offers a non-inferior bowel preparation
and an improved tolerance.
Status | Completed |
Enrollment | 858 |
Est. completion date | January 20, 2020 |
Est. primary completion date | November 10, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 69 Years |
Eligibility |
Inclusion Criteria: - Participants in the colorectal cancer screening program that give consent Exclusion Criteria: - Contraindication for colonoscopy |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Parc Taulí | Sabadell | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Hospital Parc Taulí, Sabadell |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bowel preparation | Measured with the Boston Bowel Preparation Scale from 0 until 9. 9 represents an excellent preparation. | During the colonoscopy | |
Secondary | Diet tolerance | Using Likert scale. From 1 to 5, lower is better tolerance. | It is reported before entering the endoscopy room. Regarding the 3 or 1 days on low fiber diet depending on which study group is the participant. | |
Secondary | Preparation tolerance | Using Likert scale. From 1 to 5, lower is better tolerance. | It is reported before entering the endoscopy room. Regarding the 3 or 1 day on bowel preparation depending on which study group is the participant. | |
Secondary | Adenoma detection rate | Proportion of colonoscopies with detection of colorectal cancer or adenoma excluding distal hyperplastic | up to 2 weeks after colonoscopy depending on pathology department workload. | |
Secondary | Endoscopic diagnosis | Final endoscopic diagnosis. For example; normal, diverticulosis, polyps, colorectal cancer, etc. | It is assessed during the colonoscopy and will be reported the same day. | |
Secondary | Cecum intubation rate | Cecum intubation will be assessed during each colonoscopy if the endoscope reaches the cecum. | It will be calculated through study completion, approximately 1 year, for all the study period using all participants having the colonoscopy done | |
Secondary | Intubation time | time lapse from the start of the exploration until cecum is reached. | it is assessed from the start of the colonoscopy until cecum is reached (1 day) | |
Secondary | Withdrawal time | Time lapse between cecum withdrawal the end of the exploration. | it is assessed from at the beginning of the withdrawal of the colonoscope until the colonoscopy is finished. (procedure) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A |